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Abstract
Background: B cell receptor Immunoglobulin (BcR IG) repertoire of Chronic Lymphocytic Leukemia (CLL) is
characterized by the expression of quasi-identical BcR IG. These are observed in approximately 30% of patients,
defined as stereotyped receptors and subdivided into subsets based on specific VH CDR3 aa motifs and
phylogenetically related IGHV genes. Although relevant to CLL ontogeny, the distribution of CLL-biased stereotyped
immunoglobulin rearrangements (CBS-IG) in normal B cells has not been so far specifically addressed using modern
sequencing technologies. Here, we have investigated the presence of CBS-IG in splenic B cell subpopulations (s-
BCS) and in CD5+ and CD5− B cells from the spleen and peripheral blood (PB).
Methods: Fractionation of splenic B cells into 9 different B cell subsets and that of spleen and PB into CD5+ and
CD5− cells were carried out by FACS sorting. cDNA sequences of BcR IG gene rearrangements were obtained by
NGS. Identification of amino acidic motifs typical of CLL stereotyped subsets was carried out on IGHV1-carrying
gene sequences and statistical evaluation has been subsequently performed to assess stereotypes distribution.
Results: CBS-IG represented the 0.26% average of IGHV1 genes expressing sequences, were detected in all of the
BCS investigated. CBS-IG were more abundant in splenic and circulating CD5+ B (0.57%) cells compared to CD5− B
cells (0.17%). In all instances, most CBS IG did not exhibit somatic hypermutation similar to CLL stereotyped
receptors. However, compared to CLL, they exhibited a different CLL subset distribution and a broader utilization of
the genes of the IGHV1 family.
Conclusions: CBS-IG receptors appear to represent a part of the “public” BcR repertoire in normal B cells. This
repertoire is observed in all BCS excluding the hypothesis that CLL stereotyped BcR accumulate in a specific B cell
subset, potentially capable of originating a leukemic clone. The different relative representation of CBS-IG in normal
B cell subgroups suggests the requirement for additional selective processes before a full transformation into CLL is
achieved.
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Introduction
Chronic lymphocytic leukemia (CLL) is characterized by
pronounced clinical heterogeneity that likely reflects the
underlying biological complexity (Chiorazzi and Ferrar-
ini 2011; Zenz et al. 2010). A fundamental aspect of CLL
ontogeny and evolution concerns microenvironmental
interactions mediated through various surface receptors,
amongst which the B cell receptor immunoglobulin
(BcR IG) plays perhaps the most prominent role. This is
amply demonstrated by the segregation of CLL cases
into two subgroups with widely divergent clinical
courses based on the impact of the somatic hypermuta-
tion (SHM) burden within the clonotypic rearranged
immunoglobulin heavy variable (IGHV) gene. One sub-
group exhibits high germline identity (GI ≥ 98%, Unmu-
tated or UM-CLL) and is generally associated with
adverse prognosis, whereas the other subgroup is char-
acterized by a substantial SHM load (GI < 98%, Mutated
or M-CLL) and generally presents with an indolent dis-
ease course (Damle et al. 1999; Hamblin et al. 1999).
Over the years, several independent studies have
shown that CLL displays a skewed IGHV gene reper-
toire, largely different from that of normal circulating B
cells (Schroeder Jr. and Dighiero 1994; Fais et al. 1998).
Moreover, despite the enormous potential of BcR IG di-
versity, up to 30% of CLL patients carry quasi-identical
BcR IG. Such highly restricted BcR IG were defined as
stereotyped (Messmer et al. 2004; Widhopf et al. 2004)
and patients carrying such rearrangements were classi-
fied accordingly into distinct subsets, each defined by a
unique sequence amino acid (aa) motif within the heavy
variable complementarity-determining region 3 (VH
CDR3) (Agathangelidis et al. 2012; Agathangelidis et al.
2014). Although several hundred subsets have been re-
ported to date, 19 of these were larger in size, cumula-
tively accounted for more than 10% of BcR of all CLL
clones, and were thus defined as major subsets
(Agathangelidis et al. 2012). The assignment of a given
patient to a stereotyped subset requires particular BcR
IG features including the aa length and composition of
the VH CDR3 along with the usage of a certain IGHV
gene. Specifical rules determine the degree of VH CDR3s
diversity: the assignment to the same stereotyped subset
implies at least 50% aa identity and 70% aa similarity as
well as identical VH CDR3 length and offset of the se-
quence pattern (Agathangelidis et al. 2012; Darzentas
and Stamatopoulos 2013). Moreover, these VH CDR3
have to be associated with IGHV genes belonging to the
same phylogenetic clan, i.e. genes that are evolutionarily
related, hence quite similar at the sequence level (Le
Franc Lefranc M-PaL, G 2001; Kirkham et al. 1992).
These remarkable features of the BcR IG gene reper-
toire led to the notion that antigenic stimulation is a
critical factor in the natural history of CLL (Chiorazzi
et al. 2005; Ghia and Caligaris-Cappio 2006). Several
studies have demonstrated that the outcome of antigen
engagement results in a down-modulation of sIgM in
CLL cells that appears to be less pronounced in the
UM-CLL compared to M-CLL (Stevenson et al. 2011;
Coelho et al. 2013; Apollonio et al. 2013; Drennan et al.
2019). In addition, it has been reported the possibility
that homotypic interactions between the BcR IG present
on the clonal cell surface, leading to receptor de-
clustering allow the activation of a cell autonomous sig-
naling cascade that may ultimately induce cell activa-
tion/proliferation (Duhren-von Minden et al. 2012;
Minici et al. 2017).
Stereotyped BcR IG have also been identified in other
mature B cell malignancies (Agathangelidis et al. 2019)
as well as in healthy individuals (Forconi et al. 2010; Sei-
fert et al. 2012). In more detail, stereotyped BcR IG were
evident in mantle cell lymphoma (Hadzidimitriou et al.
2011) and at lower frequencies in splenic marginal zone
lymphoma (Zibellini et al. 2010; Bikos et al. 2012). Fur-
thermore, “CLL-biased” BcR IG were found in monoclo-
nal B cell lymphocytosis, a known pre-CLL condition
(Morabito et al. 2013; Vardi et al. 2013; Agathangelidis
et al. 2017). However, very few studies have investigated
the existence of CLL-like stereotypes in settings other
than CLL with high throughput sequencing techniques
(Vergani et al. 2016) and no one in spleen B cells.
In this study, we used next generation sequencing
(NGS) to collect highly resolved information on the
presence of CLL-biased stereotyped BcR IG in splenic
normal B cell subpopulations (s-BCS). In addition, CD5+
and CD5− B cells were isolated and analyzed either from
spleen or from peripheral blood (PB). We focused on
IGHV-IGHD-IGHJ gene rearrangements utilizing
IGHV1 genes, namely the subgroup where falls 9 of the
19 major CLL stereotyped subsets (Agathangelidis et al.
2012; Darzentas et al. 2010).
Materials and methods
Sample origin
Six spleens, free of neoplastic cells at histological inspec-
tion, were obtained from the Pathology Division of the
San Martino Hospital. Spleen 19 (from a patient aged
87), spleen 25 (p. aged 81), spleen 26 (p. aged 21), spleen
32 (p. aged 31) and spleen 41 (p.aged 73) were obtained
from patients who had been splenectomized following
trauma. Spleen 713 was obtained from a patient aged 78
who had been splenectomized at surgery for a gastric
adenocarcinoma (with no spleen involvement).
PB samples were obtained from the Department of Ex-
perimental Medicine (University of Genoa) from three
normal donors aged 54 (WS), 66 (EC) and 75 (AZ), re-
spectively. This age range was selected to approximately
match the age of CLL onset.
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Isolation of splenic B cell subpopulations and
fractionation of CD5+ and CD5− B cells
Spleen cell suspensions were obtained using a gentle
Macs dissociator (Miltenyi Biotech GmbH, Bergisch
Gladbach, Germany) and mononuclear cells were sepa-
rated by density gradient separation using Ficoll Hypa-
que (Seromed; Biochrom KG, Berlin, Germany).
B cell subpopulations were isolated by staining with
mAbs tagged with different fluorochromes followed by
sorting on a two laser (488 nm and 640 nm) FACS (FAC-
SAria, Becton Dickinson Italia, Milano, Italy), as detailed
below and depicted in Supplementary Fig. 1 and Supple-
mentary Table 1. The following combination of mAbs was
employed: anti CD19 APC-Vio770 (Miltenyi Biotech); anti-
IgD Alexa Fluor 488 (BioLegend, San Diego, CA); anti-IgM
PE, anti-CD27 PE-CF594, anti-CD38 PE-Cy7, anti-CD24
Alexa Fluor 647 and anti-CD5 Alexa Fluor 700 (BD).
Operationally, splenic CD19+ B cells were first frac-
tionated according to the expression of CD38 and IgD
(Supplementary Fig. 1A, top line, center (Colombo et al.
2013). The following B cell subpopulations were then
isolated: follicular mantle (FM) B cells were isolated as
IgD++, CD38− B cells and depleted further of CD27+
cells (top line, right). Germinal center (GC) B cells were
isolated as CD38+, IgD− B cells and depleted further of
CD24+ cells (top line, left). Switched-memory (SM) B
cells were identified as IgD−CD38−IgM− (middle line,
center), while MZ B cells were separated as
IgDlow-CD38negIgM+ cells (middle line, center). Besides,
in spleens 19, 32 and 41, the IgM+ cell fraction obtained
from the CD38−, IgDlow/neg cells (middle line, center)
was separated further into IgM only (MO) B cells (IgD
negative) and MZ B cells (middle line, center) that were
further fractionated into CD27+ (MZ27+) and CD27−
(MZ27−) B cells (middle line, right). Moreover, SM B
cells were further depleted of CD27 to obtain double-
negative (DN) B cells (middle line, left). Transitional
(TR) B cells were obtained by gating CD19+ B cells ex-
pressing CD38++ and CD24++ (Supplementary Fig. 1B).
One of the spleens (SPL25) was studied only for the
main B cell subpopulations (FM, GC, MZ and SM).
Only IgM transcripts were analyzed in the majority of
the B cell subpopulation samples indicated above; both
IgM and IgG transcripts were analyzed in GC B cell
samples. Only IgG transcripts were analyzed in the case
of SM and DN B cell samples.
Cells were sorted into 200 μl PCR tubes containing
100 μl (Ambion-Thermofisher Scientific, Waltham, MA.
USA) binding lysis buffer and stored at − 20 °C.
Technical replicates were taken by isolating aliquots of
the same B cell subpopulation samples in different tubes:
they were processed and run separately, then analyzed
together for the clonal assignment in the bioinformatics
pipeline.
In order to separate CD5+ and CD5- cells from the
splenic and peripheral blood cell suspensions, CD19-
positive B cells were gated in the FACS-sorter and sub-
sequently fractionated into CD5-positive and CD5-
negative cells (Drennan et al. 2019; Darzentas et al.
2010; Seifert and Kuppers 2016).
Library preparation and sequencing
High-throughput sequencing analysis of IGHV-IGHD-
IGHJ gene rearrangements was performed on total RNA
as previously described (Vergani et al. 2017). Briefly,
mRNA was isolated using poly-T (Ambion, Thermo-
fisher) coupled with magnetic beads (Supplementary Fig.
2). Total mRNA was reverse transcribed in this solid
phase by using the poly-T as primers for the reaction.
Beads bound to cDNA were then purified with a magnet
and cDNA was used to synthetize ds-cDNA of the
IGHV-IGHD-IGHJ gene rearrangements. The original
protocol (Vergani et al. 2017) was partially modified in
spleens 713, 26 and 25 and limited to IGHV1 subgroup
genes sequencing. To this end, six different primers that
anneal to the 5′ end of the leader sequence of all IGHV1
subgroup genes were multiplexed in a single PCR (sup-
plementary M&M). PCR was performed in solid phase
in 10 μl (polymerase activation: 98 °C for 30 s, denatur-
ation: 98 °C for 15 s, annealing: 60 °C for 5 min and
elongation including final extension of: 72 °C for 5 min),
using a Q5 DNA High Fidelity DNA Polymerase (NEB,
Ipswich, MA, USA). Primers were composed of 14 to 16
random nucleotide sequences at the 5′ end and partial
Illumina Adaptor sequences as detailed in supplemen-
tary M&M.
Double-stranded cDNA was used as template for a
second PCR amplification round using a Q5 High Fidel-
ity DNA Polymerase, a universal forward primer (ILF1)
and reverse isotype specific primers mu and gamma con-
stant region that contained Illumina Adaptor sequences
(supplementary M&M). Only IGHV1 subgroup gene se-
quences associated with mu and gamma specific primers
sequences were analyzed in this study.
CD5+ and CD5− B cells isolated from PBL and were
analyzed separately from the other s-BCS.
PB CD5+ and CD5− cells and all cells from spleen 19,
32 and 41 were amplified according to the Vergani
protocol (Vergani et al. 2017) by using IGHV primers
for all the IGHV subgroups in conjunction with primers
specific for mu, gamma, delta and alfa constant regions.
Only IGHV1 subgroup gene sequences associated with
mu and gamma specific primer were analyzed in this
study.
PCR conditions were the following: 98 °C for 30 s
(polymerase activation); 22 cycles of: 98 °C for 15 s (de-
naturation), 60 °C for 30 s (annealing), 72 °C for 30 s (ex-
tension); 72 °C for 7 min (final extension). The PCR
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product was purified by using Ampure XP beads (Beck-
man Coulter, Brea, CA, USA) at ratio of 1:0.7x; 1 μl of
PCR product was run on TapeStation (Agilent Tech-
nologies, Santa Clara, CA, USA) by using the High sensi-
tivity D1000 Screen Tape to control amplicon quality.
Products were quantified with Qubit 2.0 (Thermofisher).
One ng was used to add Illumina Index Primers with the
Nextera XT kit (Illumina, San Diego, CA, USA). A 2 ×
300 bp paired end kit (MiSeq V3, 2 × 300 kit, Illumina)
was used for library generation and sequencing. The li-
brary was loaded at 12 pM with 5% PhiX. DNA se-
quences were deposited on Sequence Read Achive (SRA)
portal of NCBI with BioProject ID: PRJNA515424.
Bioinformatics analysis
In order to ensure consistency, all sequences were sub-
jected to a multi-level process of filtering. Raw NGS
reads were first processed with a custom-built workflow
using pRESTO (Vander Heiden et al. 2014) as detailed
in Supplementary M&M (Code 1). Selected IGHV1 sub-
group gene rearrangement sequences in association with
gamma or mu constant heavy chain were submitted to
the IMGT/HighV-QUEST tool (Alamyar et al. 2012).
Curated sequences were then scanned for the presence
of aa motifs within the VH CDR3 that are characteristic
for the major CLL stereotyped subsets with the applica-
tion of a previously described algorithm (Agathangelidis
et al. 2012).
After this analysis, sequences were clustered into two
distinct groups: either CLL-biased stereotyped (CBS-IG)
and non-CBS-IG (i.e. not assigned to CLL stereotyped
subsets), and then categorized into clonal families by
using ChangeO (Gupta et al. 2015). Briefly two IGHV-
IGHD-IGHJ gene rearrangement sequences were
assigned to the same clonal family if they were using the
same IGHV, and IGHJ genes, presenting a VH CDR3
with the same length and a maximum VH CDR3 nucleo-
tide distance (threshold) calculated by findThreshold
function from the SHazaM R package. Threshold values
are comprised from 0 to 1 (0 = 100% identity, 1 = 0%
identity). The optimal threshold was calculated for each
individual sample and s-BCS (supplementary Table 2).
Code commands are reported in supplementary MM
(Code 2). Briefly, recurrent sequences assigned to the
same clonal group were collapsed to a single IGHV-
IGHD-IGHJ gene rearrangement representative of each
clonal family. Figures and statistical analyses have been
made at clonal level, i.e. considering only “one represen-
tative sequence” from each clonal family. Conventionally,
the representative IGHV-IGHD-IGHJ rearrangement
was the sequence with the highest number of sequenced
mRNA molecules sequenced. Data of s-BCS and CD5+
and CD5− B cells are summarized in supplementary
Table 2.
Statistics
Statistical analyses were performed in R. Contingency ta-
bles were analyzed using Fisher’s exact test. Kruskal-
Wallis and Dunn’s tests with Bonferroni correction and
Cochrane Mantel Haenszel test were applied to assess
differences in CBS-IG frequency and in group distribu-
tions, respectively (significance at p < 0.05 in all tests).
Results
Processing of sequence data and identification of CLL-
biased stereotyped immunoglobulin gene
rearrangements (CBS-IG) of the splenic B cell
subpopulations (s-BCS)
A total of 182,783 productive, unique IGHV1 subgroup
gene rearrangement curated sequences were obtained
from 1,315,000 sorted B cells (~ 18%) from six spleens
separated as detailed in Supplementary Fig. 1. Curated
sequences were subsequently clustered into 117,027
clonal families (detailed in Supplementary Table 2). Two
hundred and seventy-nine IGHV-IGHD-IGHJ gene rear-
rangements were assigned to one of the major IGHV1
CLL stereotyped subsets corresponding to 0.24% of all
identified clonal families.
Frequency of the CLL stereotyped subsets among the
CBS-IG was different compared to CLL clones
Stereotyped BcR from CLL patients are categorized in
different subsets(9). For the sake of clarity, the features
of CLL subsets using IGHV1 genes are summarized in
supplementary Table 3.
Most CBS-IG clones were assigned to subset #12 (142
clones, 0.12% of the total clones), followed by subset
#28A (57 clones, 0.048%). Subsets #7H (21 clones,
0.018%), #3 (23 clones, 0.019%) and #5 (17 clones,
0.014%) were represented at a similar level. Subsets #6
and subset #1–99 were less represented with 10
(0.009%) and 6 (0.005%) clones, respectively. Finally, only
3 clones were detected for subset #59.
The relative frequency of the different CLL major ste-
reotyped subsets among CBS-IG rearrangements is
shown in Fig. 1a. This distribution of CBS-IG rearrange-
ments among individual major stereotyped subsets was
compared to that of CLL reported in the study by
Agathangelidis et al. (Agathangelidis et al. 2012). Because
of the study design, the comparison was restricted to
CLL sequences utilizing IGHV1 subgroup genes. The
frequency of stereotyped subsets in both the CBS-IG
and the CLL sequences is depicted in Supplementary
Fig. 3. Subset distribution was significantly different (p =
0.00049) between the two groups. For example, stereo-
typed subset #1, which is the most frequent IGHV1 sub-
set in CLL, was scarcely represented in the CBS-IG
rearrangements with just 10 clones detected. In contrast,
CBS-IG belonging to subsets #12, #28 and #7H, which
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were the most abundant amongst CBS-IG rearrange-
ments, are much less frequent in the CLL dataset.
CBS-IG were identified in most of s-BCS
The distribution of stereotyped CBS-IG among different
s-BCS showed that such rearrangements were found in
all studied s-BCS (Fig. 1b). An increased frequency was
observed in TR, FM, MZ and MZ27− B cells yet statis-
tical significance was not reached (Fig. 1b).
Subset #12 CBS-IG sequences were the most repre-
sented and this held when B cells were both considered
in bulk or subdivided into different s-BCS (see Fig. 1).
The second most used CBS-IG was subset #28A. De-
tailed data on the representation of CBS-IG in the differ-
ent s-BCS are reported in Supplementary Table 2 and
Supplementary Table 4.
IGHV1 gene usage was broader in CBS-IG compared to
CLL major subsets
Next, we compared the IGHV1 gene usage of the CBS-
IG with that of CLL clones belonging to the same major
stereotyped subsets. The CBS-IG rearrangements ex-
pressing the same IGHV1 genes as those usually found
in their respective CLL counterparts were here defined
as “typical” CBS-IG rearrangements, whereas those ex-
pressing a different IGHV1 gene were termed “non-typ-
ical”. Both typical and non–typical stereotyped CBS-IG
rearrangements were identified in all s-BCS (Supplemen-
tary Fig. 4A) revealing an overall broader usage of
IGHV1 subgroup genes by CBS-IG rearrangements than
CLL (Fig. 2). Stereotyped subsets #1–99, #3, #5, #6 and
#7H showed the highest fraction of typical CBS-IG. This
was mainly related to the preferential use of the
IGHV1–69 gene by all these subsets except subset #1–
99 (Fig. 2). In contrast, CBS-IG belonging to subsets #12
and #28A, used IGHV1 subgroup genes different from
those frequently found in CLL, with typical
rearrangements accounting only for only 18% (26/142)
and 12% (7/57) for subsets #12 and #28A, respectively
(Fig. 2 and Supplementary Fig. 4B). None of the rare
CBS-IG assigned to subset #59 were typical. Individual
stereotyped subsets within typical CBS-IG [80/279 =
28.67%] displayed different distribution in comparison
with non-typical CBS-IG rearrangements (p = 0.00049;
Fisher’s test with Monte Carlo simulated p value; supple-
mentary Fig. 4B).
CBS-IG were mostly unmutated
The mutational status of the CBS-IG was determined
using a 1% cut-off difference from the corresponding
germ line sequence. The majority of the CBS-IG rear-
rangements from all s-BCS were unmutated (257/279 or
92.1%) (Fig. 3a and b). Exceptions were: (i) SM B cells,
which included mostly mutated sequences 7/8 (87.5%)
and (ii) DN B cells, that included a fraction of mutated
sequences (3/6 or 50%) (Fig. 3a).
In the CLL dataset used in the comparison, these sub-
sets comprised only umutated sequences (except one
case belonging to subset #12) with an IGHV germline
identity above 99% (or less than 1% difference). This
finding makes the comparison between CLL rearrange-
ments and those of s-BCS CBS-IG perfectly feasible even
in consideration of the different cut-off set for distin-
guishing mutated from unmutated sequences in CBS-IG
(1%) and CLL rearrangements (2%).
Identification of CBS-IG in CD5+ and CD5− B cells from
peripheral blood and spleen
We investigated the representation of CBS-IG in CD5+
and CD5− B cells from PB of three subjects and from
three spleens. Overall, we analyzed 14,978 productive,
unique IGHV1 clones derived from 260,000 cells (details
are reported in Supplementary Table 2). The overall rep-
resentation of CBS-IG was similar in the spleen and in
a b
Fig. 1 Relative frequency of different stereotype subsets among the CBS-IG rearrangements of s-BCS. a Frequency of subsets used by CBS-IG
rearrangements of B cells considered in bulk. b Relative frequency of the subsets found among the CBS-IG rearrangements expressed by the
various s-BCS. Stereotype subsets are marked by different colours as indicated
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the PB derived B lymphocytes (0.46 and 0.61% respect-
ively). IGHV1 CBS-IG were more frequent in the CD5+
cells than in the CD5-cells (see Fig. 4a; p = 0.01 for the
spleen and p = 0.002, for the PB). Figure 4b shows the
frequency of the different CLL stereotyped subsets
among the CBS-IG of the CD5+ and CD5− B cells. Sub-
set #5 was predominant in PB CD5+ B cells and subset
#28A was the most represented in splenic CD5+ B cells,
whereas subset #1–99 was scarcely represented in all
samples studied (a single clone was identified in the
spleen CD5+ B cells). Most of CBS-IG gene rearrange-
ments of both CD5+ and CD5- B cells were unmutated,
while mutated and unmutated sequences were observed
in the non CBS-IG gene rearrangements from both
CD5+ and CD5- cells (Fig. 4c).
Discussion
The human spleen represents a useful source of s-BCS
localized in defined anatomical areas (germinal center,
mantle and marginal zone) that can be isolated based on
their surface markers (Colombo et al. 2013; Sanz et al.
2008; Weller et al. 2004). Additional markers such as
CD24, CD27 and sIg (IgM, IgD IgG and IgA) allow the
identification of transitional, memory and naïve com-
partments. Purified s-BCS enable more detailed BcR IG
repertoire analyses than unfractionated B cells, especially
for less represented populations that can escape
characterization when unfractionated B cells are ana-
lyzed. Furthermore, the splenic tissue allows for the iso-
lation of s-BCS that are normally not present in the
blood circulation (GC B cells) or, when present (MZ B
cells), represent only a small fraction of the subpopula-
tion itself (Bagnara et al. 2015; Seifert and Kuppers 2016;
Hendricks et al. 2018). The spleen provides evident ad-
vantages for normal, adult BcR IG repertoire analyses
over other secondary lymphoid tissues, such as the ton-
sils, which are frequently removed at young age and in
the case of chronic infection. With these premises, we
Fig. 2 Utilization of IGHV1 family genes by CBS-IG and by CLL stereotype rearrangements. Normal (s-BCS) CBS-IG rearrangements are classified as
typical (grey) or non-typical (white) based upon whether the IGHV1 genes utilized were the same or different from those commonly used by CLL
clones for a given rearrangement (black). The relative frequency of typical and non-typical CBS-IG in s-BCS (considered in bulk) for each
stereotype subset is reported on the right of the figure. Numbers in boxes indicate the total number of sequences investigated for each subset
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investigated up to nine s-BCS from six different human
spleens for the presence of CBS-IG sequences. In
addition, CD5+ B cells, isolated from spleen and periph-
eral blood, were investigated also in comparison with
the CD5- B cells from the same tissues. These studies
were carried out based on the hypothesis that CLL cells
may have origin from normal CD5+ B cells (Seifert et al.
2012).
CBS-IG rearrangements belonging to subset #12 were
the most represented in almost all splenic s-BCS. Se-
quences belonging to stereotyped subset #12 carry a
relatively long VH CDR3, composed of 19 amino acids
with a mainly combinatorial amino acidic sequence pat-
tern, i.e. generated primarily through the recombination
of the IGHV1/IGHD3–22/IGHJ6 genes with a minor
contribution from the N-diversity regions within the
junctions (Agathangelidis et al. 2012). This finding could
indicate a higher chance of such rearrangements to
occur since they require solely a gene combination
process. However, other IGHV1-expressing stereotyped
subsets equally characterized by combinatorial patterns
and by shorter VH CDR3 (i.e. subsets #1, #59 and #99)
were less commonly identified. Thus, the size represen-
tation of CBS-IG does not appear to merely reflect the
likelihood of recombination of the IGHV-IGHD-IGHJ
genes. Furthermore, a small number of CBS-IG se-
quences were mutated and/or isotype switched (IgG)
(Supplementary Table 4), indicating that normal B cells
carrying stereotyped BcR IG rearrangements could go
through all checkpoints during B cell differentiation.
CBS-IG displayed a broader usage of IGHV1 genes
than CLL clones and utilized most of IGHV1 subgroup
genes. Of interest, the most frequently identified CBS-IG
subsets (#12 and #28A) were also those that exhibited
an inferior representation of typical CBS-IG (see Fig. 2
and supplementary Fig. 4A). Conversely, in the less fre-
quent CBS-IG subset #1–99 only typical rearrangements
were identified (see Fig. 2 and Supplementary Fig. 4A).
Thus, these observations as well contribute to establish-
ing differences between the normal and CLL stereotype
repertoire.
To further assess the issue of B-cell compartment that
represent possible sources of CLL cells, we applied the
same techniques (NGS technology and the present bio-
informatics pipelines) to study CD5+ and CD5− B cells
derived from PB and spleen tissues for the presence of
CBS-IG rearrangements.
Overall, the data obtained indicated that CD5+ B cells
are enriched in CBS-IG compared to the CD5− B cells
both in spleen and PB tissues (see Fig. 4a and b). As for
the splenic CD5+ B cells, the relative representation of
CBS-IG CLL subsets reflected that observed in the BCS
separated in the matched samples (Supplementary Fig.
5). As for CD5+ B cells isolated from the PB samples a
more frequent representation of CBS-IG belonging to
subset #5 was observed (see Fig. 4b and Supplementary
Fig. 5). Similarly to the s-BCS described above, subset
#1–99 was not observed in PB CD5+ B cells and was
rarely identified in samples of spleen CD5+ B cells
(Fig. 4b and Supplementary Fig. 5). Likewise, subset #59
was never observed among CD5+ CBS-IG. Thus, CD5+ B
cells do not appear to have a CBS-IG repertoire reminis-
cent of that observed in CLL clones (Supplementary Fig.
5B and C).
Regarding CD5+ B cells, it is still matter of debate if
this marker can identify a truly separate lineage as it
happens in mice [reviewed in (Prieto and Felippe 2017)].
The frequency of CBS-IG identified in this study is
a
b
Fig. 3 SHM in CBS-IG rearrangements of s-BCS. a. Frequency of
mutated and unmutated rearrangements in CBS-IG and in non-
stereotyped rearrangements (non CBS-IG) in the different s-BCS as
indicated. b Frequency of mutated and unmutated CBS-IG
rearrangements stratified according to CLL stereotype subsets.
Numbers in the boxes indicate the total number of clones analyzed
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markedly lower if compared to what reported in the
study by Seifert et al (Seifert et al. 2012). This might be
due to the different number of sequences analyzed, the
more restricted set of CLL subsets investigated and
mostly, to the criteria used to define BCR stereotypy that
are more stringent in the present study.
CD5+ B cells isolated from the spleen do not seem to
carry significantly more CBS-IG when compared to the
other BCS isolated from the same sample (see Supple-
mentary Fig. 5A and B). Related to this, CD5+ B cells are
represented at various ratios in the s-BCS studied [2–8%
of CD19+ B cells in spleens vs 24–30% observed in PB
(not shown)] with an elevated variation among the sam-
ples analyzed. In addition, CD5+ (and CD5−) B cells iso-
lated for Ig rearrangement sequencing are only partially
represented in the other separated s-BCS as a significant
proportion of B cells are excluded in the separations op-
erated using the various markers (as shown in Supple-
mentary Fig. 6). Thus, it is not possible to identify a
single s-BCS that exclusively (or mostly) harbors CD5+ B
cells. Further studies are needed to get better insight
into this issue.
Some degree of heterogeneity of CBS-IG gene re-
arrangement representation was observed in the samples
from different subjects. However, in none of the samples
analyzed, similarity of repertoire with that of CLL pa-
tients was observed (Supplementary Fig. 5B and C).
Overall, most CBS-IG sequences did not show a heavy
SHM load, in analogy to that found for IGHV1-
expressing CLL major stereotyped subsets and indeed
these were mostly identified in the CBS-IG unmutated
rearrangements (Figs. 3 and 4c).
Based on the above repertoire comparisons, it can be
argued that CLL ontogeny may initiate from different
BCS and that distinct mechanisms may lead to the
emergence of cell clones with different immunogenetic
properties (Agathangelidis et al. 2012). Indeed, the ste-
reotyped BcR IG repertoire of CLL clones does not ap-
pear to reflect that of normal s-BCS and CD5+ B cells.
On the other hand, the finding that CLL stereotyped
BcR IG also can be expressed by MZ lymphoma clones,
albeit rarely (Xochelli et al. 2018), suggests that B cell
clones carrying certain BcR IG may give origin to differ-
ent lymphoproliferations. These results point towards
Fig. 4 a Box-plots of the frequency (%) of CSB-IG rearrangements in
CD5+ and CD5- B cell fractions from three PB and from three spleen
samples. Each dot represents a single individual. CD5+ B cells
expressed higher number of CBS-IG rearrangements (p = 0.002 PB;
p = 0.01 spleens) irrespective of their location, PB or spleen. b CLL
stereotyped subset distribution in the CBS-IG rearrangements of
CD5+ and CD5-B cells. CLL stereotype subsets are marked by
different colours as indicated. c Frequency of mutated and
unmutated rearrangements in CBS-IG and in non CBS-IG
rearrangements in the CD5+ and CD5-B cells as indicated
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the notion that specific microenvironment signals (fol-
licular versus extra-follicular) and/or by shared immune-
mediated mechanisms (pathogen-driven) may be crucial
for the ontogeny of lymphoid malignancies. In some in-
stances, survival of the B cells expressing unmutated
CBS-IG, particularly those shared by different individuals
and thus belonging to the “public” BcR IG repertoire
(Soto et al. 2019; Briney et al. 2019) could be warranted
by particular types of antigen stimulation. This stimula-
tion may not be leading to SHM or isotype switch and
may be occur in the absence of a relevant T cell help or
simply due to the fact their immunogenetic features are
optimal for their role. The expression of CD5 by acti-
vated, transforming B cells (and the possible conversion
to a stable expression of CD5 molecule by transformed
cells) might be part of this stimulation process, possibly
occurring during CLL leukemogenesis. However, several
points remain unresolved, such as the relationship be-
tween the expression of CD5+ B cells identified in
lymphoid tissues and those found in the circulation.
These issues might be addressed in longitudinal studies,
which are not, however, feasible on human tissues and
requiring different experimental models.
Conclusions
B cells with BcR IG rearrangements reminiscent of those
belonging to the CLL major stereotyped subsets represent a
sizeable cell fraction of the repertoire of different BCS from
normal spleens and PB including CD5+ B cells that were
significantly enriched compared to the CD5− counterpart.
However, the relative representation of CBS-IG was highly
different from that of CLL in all B cell subgroups examined.
Prime example was the rare identification of CLL subset #1,
which is the most frequent observed in CLL. These stereo-
typed sequences appear to be part of the so-called “public”
BcR IG repertoire (Soto et al. 2019; Briney et al. 2019).
Altogether, the data presented here offer new insight into
the mechanisms that are relevant to CLL ontogeny and
suggest that, although potential CLL progenitors expressing
stereotyped BcR IG are present in secondary lymphoid or-
gans and in PB, additional mechanisms appear to be neces-
sary for the generation of CLL clones.
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